Anidulafungin

證據等級: L5

預測適應症: 10 個

Anidulafungin: From Invasive Candidiasis to Impetigo

One-Sentence Summary

Anidulafungin is an echinocandin antifungal agent used in other markets for invasive candidiasis and candidemia, but it is not currently registered in Denmark. The TxGNN model assigns its highest prediction score to Impetigo (98.85%), yet mechanistic analysis identifies this as a likely false-positive driven by knowledge graph topology — the drug has no relevant antibacterial activity against this indication and 0 clinical trials and 0 publications support this direction. The most clinically credible secondary signal across all predictions is Pleural Empyema (rank 7), supported only by a single pharmacokinetic study demonstrating measurable pleural penetration.

Quick Overview

Item	Content
Original Indication	Invasive candidiasis, candidemia (not registered in Denmark; no licence data available)
Predicted New Indication	Impetigo
TxGNN Prediction Score	98.85%
Evidence Level	L5
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Anidulafungin belongs to the echinocandin class of antifungals. Although detailed mechanism of action data is not available in this Evidence Pack, the drug is well-established as a non-competitive inhibitor of β-1,3-glucan synthase — the enzyme responsible for synthesising β-1,3-glucan, a critical structural component of the fungal cell wall. Because this enzyme is entirely absent in both mammalian and bacterial cells, anidulafungin has no antibacterial activity of any kind.

Impetigo is a superficial bacterial skin infection caused by Staphylococcus aureus or Streptococcus pyogenes. Neither pathogen possesses a β-1,3-glucan synthase target, and there is no established pharmacological basis for predicting anidulafungin efficacy against them. The high TxGNN score (98.85%) most likely reflects a knowledge graph topological artefact: the “skin infection” node cluster sits in close proximity to antifungal drug nodes within the graph, generating a spurious high-scoring association without any true mechanistic link. This prediction is assessed as a false positive.

It is worth noting that a secondary prediction — Pleural Empyema (rank 7, score 98.52%, evidence level L4) — represents a marginally more plausible, though still very early-stage, hypothesis. Fungal pleural empyema caused by Candida or Aspergillus spp. does occur in critically ill and immunocompromised patients and carries high mortality. One PK/PD observational study (PMID 29439960) confirms that anidulafungin reaches measurable concentrations in pleural effusion (approximately 40–60% of simultaneous plasma levels), establishing that drug penetration to the pleural compartment is achievable. This does not constitute efficacy evidence, but it is the only data point across all predictions that carries any clinically interpretable signal.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available for the impetigo indication.

Secondary signal — Pleural Empyema (rank 7): One pharmacokinetic study is available and is included below for reference, as it represents the only published evidence identified across all predictions in this Evidence Pack.

PMID	Year	Type	Journal	Key Findings
29439960	2018	PK/PD Observational Study	Antimicrobial Agents and Chemotherapy	In 10 critically ill patients, anidulafungin concentrations in pleural effusion (0.32–2.02 µg/ml) and ascites fluid (0.12–0.99 µg/ml) were measurable but consistently below simultaneous plasma levels (2.48–13.36 µg/ml), confirming drug penetration to both compartments at clinically relevant concentrations

Denmark Market Information

Anidulafungin is not registered in Denmark. No marketing authorisations have been issued by the Danish Medicines Agency (Lægemiddelstyrelsen), and no centralised EMA marketing authorisation applies to the Danish market.

Access note: Anidulafungin is authorised in the EU under the brand name Ecalta (EMA centralised procedure) for the treatment of invasive candidiasis in non-neutropenic adults. Clinical use in Denmark would require access via a named-patient or compassionate-use pathway through Lægemiddelstyrelsen.

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked TxGNN prediction (impetigo, rank 1) has no mechanistic basis and no supporting clinical or preclinical evidence; it is assessed as a knowledge graph false positive arising from topological proximity of skin infection nodes. All remaining L5-rated predictions (malignant pleural mesothelioma, staphylococcal scalded skin syndrome, malignant visceral pleura tumour) are similarly unsupported. The only finding with any evidence (pleural empyema, rank 7, L4) is limited to drug penetration data and does not constitute an efficacy signal sufficient to advance beyond a research question.

To proceed, the following is needed:

Retrieval of the full Ecalta EU SmPC to complete the safety profile assessment (warnings, contraindications, drug interactions)
Clarification of the Danish named-patient import pathway (Lægemiddelstyrelsen §29) if compassionate clinical use is required
If the pleural empyema secondary signal is to be explored further: a dedicated literature search for case reports and case series of anidulafungin use in confirmed fungal pleural empyema, along with assessment of MIC data against relevant Candida/Aspergillus isolates
No further investment in the impetigo, malignant pleural mesothelioma, staphylococcal scalded skin syndrome, or malignant visceral pleura tumour predictions is warranted at this time
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.